UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~May~~July 318, 2024

HEALTH DISCOVERY CORPORATION

(Exact name of registrant as specified in charter)

333-62216

74-3002154

(State of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2002 SUMMIT BLVD, SUITE 300
ATLANTA, GA		30319
(Address of principal executive offices)		(Zip Code)

(404) 566-4865

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act.

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act.

☐ Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act.

Securities registered pursuant to Section 12(g) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	HDVY	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 45.0102 ~~Changes~~Departure inof ~~Registrant’s~~Directors ~~Certifying~~or ~~Accountant~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July ~~May 31~~8, 2024, ~~the~~Dr. ~~Board of~~Alan ~~Directors~~K. ~~received notice from Frazier & Deeter~~Hauser, ~~LLC~~Ph.D. ~~(“Frazier~~was &appointed ~~Deeter”),~~as ~~the~~Chief ~~independent~~Executive ~~registered~~Officer ~~public accounting firm~~ of Health Discovery Corporation (the “Company”). Following an extensive search, ~~that~~the ~~they~~Board ~~were~~of ~~resigning~~Directors ashired Dr. Hauser to replace George McGovern, the ~~Company’s~~former ~~registered~~Chief ~~accounting~~Executive Officer ~~firm~~of ~~effective~~the ~~immediately~~Company.

~~The~~Dr. ~~reports~~Hauser, ofage ~~Frazier~~65 &is a seasoned ~~Deeter~~business onexecutive ~~the~~with ~~financial~~over ~~statements~~twenty-five years of experience in the ~~Company~~life ~~for~~sciences field. Most recently, he served as the ~~fiscal~~Chief ~~year~~Executive Officer ~~ended~~of ~~December~~Arvetas 31Biosciences based in Irvine, California from 2020 to 2024. During his tenure, ~~did~~he ~~not~~advanced ~~contain~~machine ~~any~~learning-powered multiomic ~~adverse~~profiling ~~opinion~~to orenable companion diagnostics-stratified precision medicine, secured foundational capital and spatial biology collaborations, ~~disclaimer~~including ofwith ~~opinion~~the National Cancer Institute, and ~~were~~hired ~~not~~and ~~qualified~~led ora ~~modified~~multidisciplinary asteam that demonstrated proof-of-concept of the spatialomics solution. Prior to ~~uncertainty~~Arvetas, ~~audit~~Dr. ~~scope~~Hauser orwas ~~accounting~~the ~~principles~~Business Development Senior Vice President at CDx Precision Health in Chicago, ~~except~~Illinois, where ~~the~~he ~~opinion~~led ~~included~~its stratified medicine practice. In conducting Health Economics and Outcomes Research (HEOR), he built pharmacoeconomic andecision ~~explanatory~~trees ~~paragraph~~for ~~referring~~targeted tocancer ~~the~~therapy ~~Company’s~~clinical ~~ability~~trials that generated $250 million in cost savings. Dr. Hauser also created value by developing and executing strategic biotech innovation-to-commercialization ~~continue~~roadmaps asencompassing aproduct-intellectual ~~going~~property ~~concern~~competitive landscaping and ROI-guided partnering.

~~During the Company’s~~Dr. ~~two~~Hauser ~~most~~is ~~recent~~a ~~fiscal~~Certified ~~years~~Licensing ~~and~~Professional ~~through~~who ~~the~~received ~~date~~his ofundergraduate ~~this~~degree ~~Current~~from ~~Report~~North onCarolina ~~Form~~State ~~8-K~~University ~~(i)~~and ~~there~~his ~~were~~M.S. ~~no disagreements with Frazier &~~and ~~Deeter~~Ph.D. on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to Frazier & Deeter’s satisfaction, would have caused Frazier & Deeter to make reference to the subject matter in ~~connection~~Chemical ~~with their reports on the Company’s financial statements for such years;~~ and ~~(ii)~~Biomolecular ~~there~~Engineering ~~were~~from ~~no reportable events, within~~ the ~~meaning~~University ~~set forth in Item 304(a)(1)(v)~~ of ~~Regulation~~California, ~~S-K~~Berkeley.

~~The~~As Chief ~~Company~~Executive ~~provided~~Officer, aDr. ~~copy of~~Hauser’s ~~the~~vision ~~foregoing~~for ~~disclosures~~the toCompany ~~Frazier~~includes &but ~~Deeter~~is ~~prior~~not limited to: ~~the~~1) ~~date~~evaluation of the ~~filing~~Company’s Intellectual ofProperty ~~this~~Portfolio; ~~Current~~2) ~~Report~~exploration onand ~~Form~~development ~~8-K~~of ~~(this~~commercial ~~“Report”~~opportunities for the Company; 3) protection and ~~requested~~enforcement of ~~that~~the ~~Frazier~~Company’s &Intellectual ~~Deeter~~Property ~~furnish~~Portfolio itper ~~with~~results aof ~~letter~~evaluation; ~~addressed~~4) tocompletion ~~the~~of ~~U.S.~~necessary ~~Securities~~Internal ~~and~~Revenue ~~Exchange~~Service requirements ~~Commission~~to ~~stating~~bring ~~whether it~~Company ~~agrees~~current; ~~with~~and ~~the~~5) ~~above~~satisfaction ~~statements~~of obligations and, ifcurrent itrequirements ~~does~~of ~~not~~the ~~agree,~~Securities ~~the~~Exchange ~~respects~~Commission for inpurposes ~~which~~of itCompany’s ~~does~~common ~~not~~stock ~~agree~~listing.

~~The~~Dr. ~~full~~Hauser’s ~~board~~compensation will include a base salary of ~~directors~~$180,000 per year (pro-rated for any partial year of service) and a grant of 1,000,000 shares of restricted ~~acts~~common asstock of the Company, with the Initial Share Award vesting July 8, 2025, subject to his continued employment by the Company for such period. Dr. Hauser will receive the following performance-based stock awards, subject to the achievement of certain performance goals and his continued employment: (i) upon his completion of six months of employment with the Company, he shall be granted an ~~audit~~additional 500,000 ~~committee~~shares of the Company’s common stock; and ~~will~~(ii) upon his completion of twelve months of employment, he shall be ~~provided~~granted aan additional ~~copy~~500,000 shares of the 8kCompany’s ~~filing~~common stock. These awards will be subject to vesting requirements.

~~Item~~Board ~~9.01~~members ~~Financial~~Colleen Hutchinson ~~Statements~~ and ~~Exhibits~~Edward Morrison stated:

~~(d)~~“We ~~Exhibits~~are excited to welcome aboard Dr. Alan Hauser. Dr. Hauser’s credentials, experience, and vision for Health Discovery Corp align with the Board’s goals for the Company. Alan has an ambitious plan for Health Discovery, the implementation and scope of which will serve as a guiding framework for the foundation of a successful future for this Company.”

Exhibit No.	Description
16.1	Letter of Frazier & Deeter, LLC dated June 6, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

2SIGNATURES

~~SIGNATURES~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	HEALTH DISCOVERY CORPORATION
	Registrant

Dated: July 11, 2024	By:	/s/ Colleen Hutchinson
		Colleen Hutchinson Board Member

	HEALTH DISCOVERY CORPORATION
	Registrant
Dated: June 6, 2024	By:	/s/ Colleen Hutchinson
		Colleen Hutchinson Board Member

Filing Compare · HEALTH DISCOVERY CORP